Introduction
Therapy of metastatic melanoma (MM) remained unsatisfactory for many decades. A range of various treatment modalities based on chemotherapy has had little impact on survival (1) . As a single agent, dacarbazine (DTIC) has been commonly used (2) . Some investigators substitute DTIC with temozolomide (related oral alkylating agent) for its convenience of administration and its central nervous system penetration. A phase 3 trial comparing an extended schedule of temozolomide with a standard dose single agent DTIC failed however to show any statistical differences in terms of response rates, progression-free and overall survivals (3, 4) .
Temozolomide produces response rates of 4.13% and a median progression free survival of 1.9 months in patients without brain metastases. More recently, advances in understanding the genetic changes associated with melanoma development identified activating mutations in the serine/threonine kinases BRAF (5), establishing mitogen-activated protein kinase signaling pathways as new drug targets in melanoma. Sorafenib, a multikinase inhibitor of VEGFR, KIT, PDGFR, and RAF proteins as well as several pro-angiogenic tyrosine kinases, was tested in phase 2 trials alone or in combination with carboplatin and paclitaxel and appeared promising on response rates and median progression free survival, but was associated with toxicity (6) .
Unfortunately, subsequent phase 3 trials of the combination of sorafenib and paclitaxel/carboplatin only demonstrated benefit in patients with metastatic melanoma in first and second line of therapy (7, 8) . Next, and before the era of more specific BRAF inhibitors, Flaherty and colleagues conducted a phase 2 trial combining temozolomide with sorafenib in advanced melanoma, showing relative safety and activity in patients without prior history of temozolomide (9) . In parallel, attempts to harness antitumor immunity have progressively led to therapeutic success in melanoma (10) . Anti-CTLA-4 antibodies alone or together with peptide-based vaccination or with dacarbazine significantly prolonged survival of stage III/IV melanoma in two phase 3 trials (10, 11) . One surmises that in patients responding to immunotherapy, tumor-and/or vaccine-specific T cells reset local tumor microenvironment and convert immune tolerance into immune-related tumor destruction (12).
Since vaccines showed some unexpected efficacy after tumor progression with cytotoxic compounds (13, 14) , a new concept emerged whereby the host immune system could contribute to the beneficial effects of cytotoxic compounds (15) . Indeed, the outcome of chemotherapy can be influenced by the host immune system at multiple levels. Chemotherapy can kill cancer cells in a way that they elicit an immune response (16) or, alternatively, increase their susceptibility to immune attack (17) . In addition, chemotherapy can stimulate anticancer immune effectors either directly (by activating effector or dendritic cells) or indirectly by subverting immunosuppressive mechanisms (18, 19) . Hence, a recent report pointed out that MM patients responding to dacarbazine exhibit a stromal and immune signature, defined by hallmarks of T-cell infiltration and MHC class II expression (20) .
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TIL preparations.
Resected lymph node (LN) specimens and/or metastatic tissue from sixteen MM patients were analyzed for infiltrating lymphocytes. Tissue samples were placed in dissociation medium, i.e. RPMI1640, 1% PEST, Collagenase IV (8000 UI/mL), Hyaluronidase (112000 IU/mL), and DNAse (12700 IU/mL), and run on a gentleMACS Dissociator (Miltenyi Biotec). The cell samples were then diluted in RPMI1640 + 10% human AB + serum, passed through a cell strainer and centrifuged for 10 minutes at 300g. Next, the cells were resuspended in PBS and stained for flow-cytometric analyses. Tumor-coupled specimens of non-invaded LN or blood samples was obtained from ten patients and were analyzed as above. The qRT-PCR data was adjusted to β 2M measurements using the 2-ΔCT method (28) . In accordance with a previous report (9) , the sorafenib and temozolomide combination therapy (schedule summarized in Supplementary Fig. S1 ) induced 1 complete response (CR), 4 partial responses (PR) and 21 disease stabilizations (SD) at 3 months (CR+PR+SD called hereafter "responders") and 37 progressive disease (PD) being referred to as "non responders" according to RECIST criteria (Table 1) . Severe lymphopenia was observed in both responders and non responders ( Supplementary Fig. S2A-B) .
We phenotyped circulating lymphocytes in a longitudinal study over two months in 63 patients included in this phase 1/2 trial. All MM patients showed a significant reduction of (Fig. 1D) . (Fig. 3C) . To further characterize the functions of these cells, we performed three additional assays (Supplementary Fig. S4 ). S4C ). Sorafenib exposure did not enhance their cytotoxicity, which might be explained by the reported direct inhibitory activity of sorafenib on T-cell functions (32) . Moreover, as shown in Figure 4 , IL-15Rα expression was only weakly increased (Fig. 4D) on the cell surface of MEL10 cells by sorafenib treatment (Fig. 4E) , which could explain why the addition of IL-15 to engage CD122 was mandatory for the MEL10 cell line. To follow up on this, we then switched to the melanoma cell line MEL888, of which sorafenib had shown greater impact on the expression of IL-15Rα both on mRNA levels and cell surface  ( fig. 4E and 4D) , and tested the activation of Fig. S4D ). 
Thus, CD4 + NKG2D + T lymphocytes constituted an effector memory Th1-polarized T cell subset capable of releasing cytokines upon TCR engagement with a strong co-stimulatory activity of the NKG2D receptor or upon co-engagement of CD122 and NKG2D receptors.
Regulation of IL-15Rα expression by sorafenib in tumor beds.
We analyzed how sorafenib or temozolomide could modulate the expression of the ligands for these receptors in vitro and in vivo. Lymph-node residing melanoma was reported to express low levels of NKGD ligands (33) . We analyzed sixteen "paired" but independent tumors (mostly from subcutaneous lesions), before and after 3 cycles of therapy by immunohistochemistry of paraffin-embedded melanoma. First, anti-CD3, -CD4 and -CD8 antibody stainings revealed abundant infiltrates that were not significantly altered by therapy (Table 2 , Supplementary Fig. S5 ). The SR99 Ab recognizing MICA/B revealed that the intensity of the staining appeared moderate to strong on plasma membrane and in the cytosol in all specimen regardless of the location ( Supplementary Fig. S5 , Table 2 ). Of note, no staining was observed in the epidermal or mesenchymal cells of normal skin adjacent to the melanoma (not shown). The expression of MICA/B proteins was maintained by the therapy in tissue sections (Table 2 ) although sorafenib could, with increasing concentrations, downregulate MICA expression on melanoma cell lines in vitro, especially on MEL888 cells (Fig. 4A) . Note that treating the MEL888 cells with 10 µM sorafenib for 24h led to the release of sMICA/B in the supernatant (not shown).
We also monitored the IL-15Rα expression on tumor cells. Immunofluorescence analyses of paired melanoma pre-and post-therapy using anti-IL-15Rα specific antibodies revealed that in Fig. S2C and not shown).
However, lymphopenia at baseline influenced overall survival. Considering that median survival of the whole cohort is 227 days, patients with prolonged survival (>227 days) exhibited higher lymphocyte counts at baseline compared with rapidly progressive patients (Fig. 5A) . Importantly, the increase of circulating CD4 Fig. S6 ).
In the absence of IL-15Rα induction, however, many strategies could be envisaged to compensate these patients. Cis-or trans-stimulating IL-2Rβγ through stabilized IL-15-based approaches have been tested in preclinical models (47) . 
